Roberto Carlesi

3.1k total citations · 1 hit paper
15 papers, 2.0k citations indexed

About

Roberto Carlesi is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Roberto Carlesi has authored 15 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Surgery and 7 papers in Oncology. Recurrent topics in Roberto Carlesi's work include Gastric Cancer Management and Outcomes (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Gastrointestinal Tumor Research and Treatment (3 papers). Roberto Carlesi is often cited by papers focused on Gastric Cancer Management and Outcomes (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Gastrointestinal Tumor Research and Treatment (3 papers). Roberto Carlesi collaborates with scholars based in Italy, United States and South Korea. Roberto Carlesi's co-authors include Atsushi Ohtsu, Kei Muro, Kumari Chandrawansa, Yasuhiro Shimada, Eric Van Cutsem, Philippe Rougier, David Cunningham, Naotoshi Sugimoto, H. Wilke and Shuichi Hironaka and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Roberto Carlesi

15 papers receiving 1.9k citations

Hit Papers

Ramucirumab plus paclitaxel versus placebo plus paclitaxe... 2014 2026 2018 2022 2014 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    2014 1.7k citations H. Wilke, Kei Muro et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roberto Carlesi Italy 8 1.4k 1.0k 657 539 383 15 2.0k
Kumari Chandrawansa United States 13 1.6k 1.1× 1.4k 1.3× 695 1.1× 573 1.1× 470 1.2× 20 2.4k
Mikito Inokuchi Japan 27 1.2k 0.8× 560 0.5× 768 1.2× 484 0.9× 595 1.6× 82 2.0k
Ta-Sen Yeh Taiwan 14 1.3k 0.9× 538 0.5× 775 1.2× 596 1.1× 257 0.7× 22 1.8k
Pooja Bhagia United States 19 1.4k 1.0× 1.5k 1.5× 1.0k 1.6× 413 0.8× 246 0.6× 59 2.3k
Hideto Fujita Japan 21 508 0.4× 584 0.6× 402 0.6× 232 0.4× 417 1.1× 95 1.3k
Toshikazu Akiya Japan 8 1.5k 1.0× 852 0.8× 583 0.9× 664 1.2× 150 0.4× 12 1.7k
Darrel P. Cohen United States 13 788 0.5× 280 0.3× 261 0.4× 621 1.2× 288 0.8× 31 1.2k
Jan J. Koornstra Netherlands 18 463 0.3× 524 0.5× 424 0.6× 200 0.4× 413 1.1× 32 1.5k
G. Kurteva United States 10 678 0.5× 686 0.7× 254 0.4× 199 0.4× 180 0.5× 26 1.0k
Akira Ooki Japan 20 456 0.3× 617 0.6× 331 0.5× 97 0.2× 595 1.6× 98 1.4k

Countries citing papers authored by Roberto Carlesi

Since Specialization
Citations

This map shows the geographic impact of Roberto Carlesi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Carlesi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Carlesi more than expected).

Fields of papers citing papers by Roberto Carlesi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Carlesi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Carlesi. The network helps show where Roberto Carlesi may publish in the future.

Co-authorship network of co-authors of Roberto Carlesi

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Carlesi. A scholar is included among the top collaborators of Roberto Carlesi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Carlesi. Roberto Carlesi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Cascinu, Stefano, G. Bodoky, Kei Muro, et al.. (2020). Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. The Oncologist. 26(3). e414–e424. 4 indexed citations
2.
Valle, Juan W., Li‐Yuan Bai, Р. В. Орлова, et al.. (2020). Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.. Journal of Clinical Oncology. 38(4_suppl). 477–477. 23 indexed citations
3.
Saleh, Mansoor N., Philippe A. Cassier, Lauriane Eberst, et al.. (2020). Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. The Oncologist. 25(11). e1628–e1639. 8 indexed citations
4.
Saleh, Mansoor N., Philippe A. Cassier, Lauriane Eberst, et al.. (2019). Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study. Annals of Oncology. 30. iv124–iv124. 1 indexed citations
5.
Chen, Li‐Tzong, Do‐Youn Oh, Min‐Hee Ryu, et al.. (2017). Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Cancer Research and Treatment. 49(4). 851–868. 51 indexed citations
6.
7.
Muro, Kei, Sang Cheul Oh, Yasuhiro Shimada, et al.. (2015). Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. Journal of Gastroenterology and Hepatology. 31(3). 581–589. 31 indexed citations
8.
Wilke, H., Kei Muro, Eric Van Cutsem, et al.. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet Oncology. 15(11). 1224–1235. 1715 indexed citations breakdown →
9.
10.
11.
Bernareggi, A., A. Crema, Roberto Carlesi, et al.. (1995). Stereoselective pharmacokinetics of moguisteine metabolites in healthy subjects. European Journal of Drug Metabolism and Pharmacokinetics. 20(4). 263–270. 2 indexed citations
12.
Foresi, Antonio, Andrea Pelucchi, Berardino Mastropasqua, Roberto Carlesi, & L Marazzini. (1994). Clinical Potential of Inhaled Diuretics in Asthma. Clinical Immunotherapeutics. 1(6). 399–405. 2 indexed citations
13.
Sarcina, Antonio, Roberto Carlesi, Raffaello Bellosta, & G Agrifoglio. (1993). In Situ Saphenous Vein Bypass for Limb Salvage. Cardiovascular Surgery. 1(1). 33–37. 5 indexed citations
14.
Foresi, Antonio, et al.. (1992). Effect of Inhaled Furosemide and Torasemide on Bronchial Response to Ultrasonically Nebulized Distilled Water in Asthmatic Subjects. American Review of Respiratory Disease. 146(2). 364–368. 26 indexed citations
15.
Castoldi, D, et al.. (1990). Single dose kinetics of moguisteine in healthy male volunteers after oral and rectal administration. Pharmacological Research. 22. 102–102. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kumari Chandrawansa Breakdown of academic impact, for papers by Mikito Inokuchi Breakdown of academic impact, for papers by Ta-Sen Yeh Breakdown of academic impact, for papers by Pooja Bhagia Breakdown of academic impact, for papers by Hideto Fujita Breakdown of academic impact, for papers by Toshikazu Akiya Breakdown of academic impact, for papers by Darrel P. Cohen Breakdown of academic impact, for papers by Jan J. Koornstra Breakdown of academic impact, for papers by G. Kurteva Breakdown of academic impact, for papers by Akira Ooki
Rankless by CCL
2026